PET/CT in the evaluation of colorectal carcinoma

Applied Radiology

Volumn 37, Issue 11, 2008, Pages 33-42

  Moadel, Renee M ^a   Feng, Janine ^a   Freeman, Leonard M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; YTTRIUM 90;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLONOSCOPY; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; DRUG EXCRETION; DRUG UPTAKE; EARLY DIAGNOSIS; ENDOSCOPIC BIOPSY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; RADIOFREQUENCY ABLATION; TREATMENT RESPONSE;

EID: 57049123769     PISSN: 01609963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics. 1999;1 9(1):61-77.
2. Kim S, Chung JK, Kim BT, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in wholebody PET. Clin Positron Imaging. 1999;2(5):273-279.
3. Jadvar H, Schambye RB, Segall GM. Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. Clin Nucl Med. 1999; 24(12): 965-967.
4. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med. 1998;23(1):3-7.
5. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. Semin Nucl Med. 1996;26(4):308-314.
6. Fenogilio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Isaacson PG, eds. Gastrointestinal Pathology: An Atlas and Text. 3rd edition. Philadelphia, PA: Lippincott Williams and Wilkins; 2007:1163.
7. Groves AM, Kayani 1, Dickson JC, et al. Oral contrast medium in PET/CT: Should you or shouldn't you? EurJ Nucl Med Mol Imaging. 2005;32(10):1160-1166.
8. Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: Introduction and evaluation. Radiology. 2004;230(3):879-885. Epub 2004 Feb 5.
9. Gontier E, Fourme E, Wartski M, et al. High and typical (18)F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35(1): 95-99.
10. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose, uptake: Correlation with colonoscopic and histopathologic findings. Radiology. 2002;224(3):783-787.
11. Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre-)malignant colonic abnormalities: Endoscopic validation of FDG-PET findings. Eur J Nucl Med. 2001; 28(12):1766-1769.
12. Israel O, Yefremov N, Bar-Shalom R, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: Incidence, localization patterns, and clinical significance. J Nucl Med. 2005;46(5):758-762.
13. Gutman F, Alberini JL, Wartski M, at al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol. 2005;185(2):495-500.
14. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: A marker for poor prognosis. Cancer. 1998;83(1):34-40.
15. Sakashita M, Aoyama N, Minami R, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: Its relationship to clinicopathological features. Eur J Cancer. 2001;37(2):204-209.
16. Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med. 2007;48(7):1053-1059.
17. Neurath MF, Vehling D, Schunk K, et al. Noninvasive assessment of Crohn's disease activity: A comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol. 2002;97(8):1978-1985.
18. Löffler M, Weckesser M, Franzius C, Schober O, Zimmer KP. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann NY Acad Sci. 2006;1072:379-385.
19. Kresnik E, Gallowitsch HJ, Mikosch P, et al. (18)F-FDG positron emission tomography in the early diagnosis of enterocolitis: Preliminary results. Eur J Nucl Med Mol Imaging. 2002;29(10):1389-1392.
20. Meisner RS, Spier BJ, Einarsson S, et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis. 2DD7;13(8):993-1000.
21. Kantorová I, Lipská L, Bâlohlávek O, Visokai V, Trubac M, Schneiderová M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: Comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003; 44(11):1784-1788.
22. Nahas CS, Akhurst T, Yeung H, et al. Positron emission tomography detection of distant metastatic or synchronous disease in patents with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol. 2008;15(3):704-711.
23. Squillaci E, Manenti G, Mancino S, et al. Staging of colon cancer: Whole-body MRI vs. whole-body PET-CT-initial clinical experience. Abdom Imaging. 2008 Mar 29. [Epub ahead of print.]
24. Kong G, Jackson C, Koh DM, et al. The use of (18)F-FDG PET/CT in colorectal liver metastases - comparison with CTand liver MRI. EurJ Nucl Med Mol Imaging. 2008;35(7):1323-1329.
25. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240(3):438-447.
26. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005;104(12):2658-2670.
27. Chin K, Finger PT, Kurli M, Tena LB, Reddy S. Second cancers discovered by (18)FDG PET/CT imaging for choroidal melanoma. Optometry. 2007; 78(8):396-401.
28. Sarikaya I, Bloomston M, Povoski SP, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol. 2007;5:64.
29. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era? J Clin Oncol. 2007;25(35):5649-5654.
30. Pulitanò C, Arru M, Catena M, et al. Results of preoperative hepatic arterial infusion chemotherapy in patients undergoing liver resection for colorectal liver metastases. Ann Surg Oncol. 2008;15(6):1661-1669.
31. Yamagami T, Kato T, Tanaka O, Hirota T, Nishimura T. Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2005;16(4):549-554.
32. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711-1720.
33. Donckier V, Van Laethem JL, Goldman S, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol. 2003;84(4):215-223.
34. Riedl CC, Akhurst T, Larson S, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48(5):771-775.
35. Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T. Radiofrequency ablation versus resection for resectable colorectal liver metastases: Time for a randomized trial? Ann Surg Onool. 2008;15(1):144-157.
36. Jiao LR, Szyszko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol. 2007;33(5):597-602.
37. Warwick R, Page R. Resection of pulmonary metastases from colorectal carcinoma. Eur J Surg Oncol. 2007;33 Suppl 2:S59-63.
38. Hiraki T, Gobara H, Iishi T, et al. Percutaneous radiofrequency ablation for pulmonary metastases from colorectal cancer: Midterm results in 27 patients. J Vasc Intent Radiol. 2007;18(10):1264-1269.
39. Capirci C, Rubello D, Chierichetti F, et al. Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006;187(2):W202-208.
40. Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008; 71(1):180-186.
41. de Geus-Oei LF, van Laarhoven HW, Visser EP, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008;19(2):348-352.
42. Bowne WB, Lee B, Wong WD, et al. Operative salvage for locoregional recurrent colon cancer after curative resection: An analysis of 100 cases. Dis Colon Rectum. 2005;48(5):897-909.
43. Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: Resection determines outcome. Arch Surg. 2006;141(5):460-466.
44. Yedibela S, Klein P, Feuchter K, et al. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol. 2006; 13(11):1536-1544.
45. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC. (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol. 2007;13(37):5025-5029.
46. Soyka JD, Veit-Haibach P, Strobel K, et al. Staging pathways in recurrent colorectal carcinoma: Is contrast-enhanced 18F+DG PET/CT the diagnostic tool of choice? J Nucl Med. 2008;49(3):354-361.
47. Shen YY, Liang JA, Chen YK, Tsai CY, Kao CH. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Hepatogastroenterology. 2006; 53(69):348-350.
48. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med. 2001;28(12):1758-1765.
49. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: A prospective study. J Nucl Med. 2002; 43(4):492-499.
50. Scott AM, Gunawardana DH, Kelley B, et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: Results of a multicenter prospective study. J Nucl Med. 2008;49(9):1451-1457.
51. Kim JH, Czemin J, Allen-Auerbach MS, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005;46(4):587-595.